On May 16 2023, PROQR THERAPEUTICS N.V ($NASDAQ:PRQR). released its earnings report for the first quarter of FY2023 ending March 31 2023. Total revenue for the quarter decreased by 46.3%, amounting to EUR 0.7 million, while net income was EUR -8.9 million, a positive change from -14.4 million reported in the same quarter of the previous year.
On Tuesday, PROQR THERAPEUTICS N.V reported their financial results for the fiscal year 2023 Q1, which ended on March 31 2023. The company’s stock initially opened at $1.9 but closed the day at $1.8, a drop of 7.3% from its previous closing price of $1.9. However, analysts remain positive on the company’s outlook and believe that the company will continue to make strides in its research and development efforts, which should eventually lead to higher earnings in the foreseeable future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for PRQR. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PRQR. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PRQR. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for PRQR are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has analyzed the fundamentals of PROQR THERAPEUTICS N.V and classified it as a ‘cheetah’, which indicates that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. What type of investors may be interested in such a company? GoodWhale’s analysis reveals that PROQR THERAPEUTICS N.V has an intermediate health score of 4/10 with regard to its cashflows and debt, indicating that it is likely to safely ride out any crisis without the risk of bankruptcy. Additionally, GoodWhale assesses PROQR THERAPEUTICS N.V to be strong in asset, growth, but weak in dividend, profitability. Therefore, investors who are able to tolerate higher risk may find this company suitable for their investment portfolios. More…
Risk Rating Analysis
Star Chart Analysis
It is among the leading firms in the industry and is competing with other companies such as Merus NV, Aileron Therapeutics Inc, and Vera Therapeutics Inc to develop groundbreaking therapies for patients worldwide.
Merus NV is a biotechnology company based in the Netherlands. Founded in 2015, the company is focused on developing therapeutic antibodies for cancer and autoimmune diseases. Merus NV has a market cap of 1.03B as of 2023 and a Return on Equity (ROE) of -45.66%. This market capitalization suggests that it is a mid-sized company, as it is significantly smaller than many of its larger peers in the biotechnology sector. The company’s Return on Equity, however, is not impressive, coming in at -45.66%. This indicates that Merus NV is having difficulty generating profits from its operations.
– Aileron Therapeutics Inc ($NASDAQ:ALRN)
Aileron Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies that modulate and restore healthy cellular aging processes. Based in Boston, Massachusetts, Aileron has a market capitalization of 7.04M as of 2023, indicating a relatively small size compared to its larger peers. It also shows a negative return on equity of -88.21%, suggesting that the company has yet to generate profits or return any value to shareholders. Nonetheless, Aileron continues to be an innovator in the field of cellular aging, exploring new pathways to combat age-related disease and extend healthy human life expectancy.
– Vera Therapeutics Inc ($NASDAQ:VERA)
Vera Therapeutics Inc is a biopharmaceutical company that specializes in discovering and developing novel immune-modulating therapeutics. Currently, the company has a market capitalization of 336.83 million as of 2023. This market cap indicates the size and value of the company and its potential for growth. Additionally, Vera Therapeutics Inc has a Return on Equity (ROE) of -53.43%, indicating that the company is not utilizing its shareholders’ equity efficiently. Nevertheless, Vera Therapeutics Inc is continuing to develop novel therapeutics and is looking to increase ROE in the near future.
PROQR Therapeutics N.V has reported their first quarter earnings for FY2023 with total revenue of EUR 0.7 million, a decrease of 46.3%, and net income of EUR -8.9 million, an improvement from -14.4 million from the same quarter a year ago. Analysts are generally bearish on the stock, given the steep decline in revenue and the lack of positive news that could support a rally. Investors should carefully assess the company’s overall fundamentals before making any decisions; however, in the near-term, a bearish outlook is likely to remain.